LEXINGTON, Mass., May 5, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Development Officer, Jonathan B. Zung, Ph.D. to purchase a total of 500,000 shares of Curis common stock, with a grant date of May 1, 2023 (the "Inducement Grant").
Read more at prnewswire.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/amazon%20holiday%20delivery%20boxes%20by%20Cineberg%20via%20iStock.jpg)
